Shares of Metis TechBio-P (07666) have surged more than 10%. At the time of writing, the stock is up 10.42% to HK$14.41, with a turnover of HK$14.33 million.

This year has seen a flurry of collaboration and deal activity in the global AI biopharma sector. Notable developments include NVIDIA and Eli Lilly's plan to invest up to $1 billion over five years to build an AI drug R&D lab; Google DeepMind's Isomorphic Labs completing a $2.1 billion Series B financing round; and Insilico Medicine's AI-driven drug discovery collaboration with South Korea's SK Biopharmaceuticals in the neuroimmunology field.

Analysts suggest that leading domestic AI drug discovery companies are making innovative breakthroughs. They are intensifying efforts in areas like discovering novel drug candidates and material development, diversifying their strategies, and accelerating the transition from proof-of-concept to clinical validation and commercialization. Metis TechBio-P is among the companies highlighted for attention.

The company's core competitive strength stems from its self-developed NanoForge platform, claimed to be the world's first AI-powered nanodelivery platform. Leveraging NanoForge, the company has built a pipeline of over 10 product candidates. Among these, three leading clinical-stage assets—MTS-004, MTS-201, and MTS-105—target disease areas with significant unmet clinical needs and strong commercial potential.

Notably, Metis TechBio-P possesses MTS-004, described as China's first AI-enabled novel drug formulation to complete a Phase III clinical trial. MTS-004 is also cited as China's first and only drug to complete clinical trials for Pseudobulbar Affect (PBA), potentially addressing a treatment gap in the domestic market for this condition.